Antimicrobial Drug Discovery Overview

Principles

Definition

Antimicrobial drug discovery is a multidisciplinary research field dedicated to the systematic identification, development, and optimization of novel chemical compounds or biological agents possessing potent activity against pathogenic microorganisms. This critical process encompasses the search for new drug candidates, evaluation of their efficacy and safety, and assessment of their pharmacological profiles, ultimately aiming to combat infectious diseases and address the global threat of antimicrobial resistance.

Ontological type

Resistance Challenges

Core Methods

Target Identification

Key developments

Key Figures

Screening and Synthetic Innovation era

Selman Waksman and his Rutgers team exemplified industrial-scale screening of soil microbes, converting fermentation hits into clinically useful antibiotics and establishing production pipelines. Albert Schatz, working with Waksman, co-discovered streptomycin and helped validate the natural-product library approach that dominated this period. Giuseppe Brotzu’s discovery of cephalosporin C in 1948 opened a new class of antibiotics and spurred large-scale fermentation programs and subsequent diversification in the 1950s and 1960s. In parallel, collaborations between academia and industry advanced structure-activity considerations and semi-synthesis, enabling scaffold modification to broaden spectrum and improve stability, and shaping the later shift toward rational antibiotic design.

Mechanism-Guided Optimization era

Julian Davies [1] was a leading figure in antimicrobial drug discovery during Mechanism-Guided Optimization (1963-2003), with affiliations at Harvard University [2] and Princeton University [3] in this era. His key contribution in 1973 was the paper Aminoglycoside Antibiotic-Inactivating Enzymes in Actinomycetes Similar to Those Present in Clinical Isolates of Antibiotic-Resistant Bacteria [4], which demonstrated enzymatic inactivation as a resistance mechanism and underscored its implications for mechanism-informed drug design. This work helped institutionalize the links between structure, binding, and function and thereby informed the optimization strategies that defined the era. Ongoing scholarship at Harvard University [2] and Princeton University [3] continued to build on Julian Davies [1]'s enzymology-informed view of resistance, shaping both research directions and clinical stewardship.

Data-Driven Resistome Discovery era

Gerard D. Wright[1] is a prominent figure in antimicrobial drug discovery during the Data-Driven Resistome Discovery era, with affiliations at Harvard University[2] and McMaster University[3]. His key contributions in this era include the foundational claim that antibiotic resistance is ancient[4] and the demonstration in Sampling the Antibiotic Resistome[5] of widespread resistomes, which underpins the rationale for genome mining and resistome annotation as essential prioritization steps. These insights propelled Wright[1] to develop explainable AI-infused discovery pipelines that couple predictive scaffold selection with mechanistic interpretation, a cornerstone of mechanism-informed antimicrobial discovery in this era. Collaborative efforts across institutions such as Harvard University[2] and McMaster University[3] facilitated cross-study surveillance and scalable workflows that integrate computational annotation, modeling, and chemistry for rapid mechanism-informed antimicrobial discovery.